Pediatric Acute Respiratory Distress Syndrome (ARDS) Management Trial

Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age2-17
SponsorChildren's Hospital of Philadelphia

About this trial

Acute respiratory distress syndrome (ARDS) is a serious and potentially life-threatening lung condition that can affect children. Currently, ventilator settings commonly used in treatment are based on approaches developed for adults, and it remains unclear whether these settings are equally effective for children. Because children's bodies respond differently than adults', it is important to determine the most effective ventilator strategies specifically for pediatric patients. This study will compare two different ventilator approaches in children with ARDS to identify which method provides the greatest benefit. The findings will also help inform the design of a larger study in the future.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

age > 2 weeks (> 38 weeks corrected gestational age) and < 18 years (not yet had 18th birthday)

acute (≤ 7 days of risk factor) respiratory failure requiring invasive mechanical ventilation

ventilated with endotracheal tube or tracheostomy for ≤ 7 days from risk factor onset

hypoxemia defined as PaO2/FIO2 (measurement of the amount of oxygen dissolved in the blood plasma/concentration of inhaled oxygen) > 300 (or SpO2/FIO2 (measurement of the percentage of hemoglobin in your blood that is carrying oxygen/concentration of inhaled oxygen) > 315 on Positive End-Expiratory Pressure (PEEP) ≥ 5 cmH2O (rate of pressure delivery) on two consecutive measurements 4 hours apart and sustained at the time of consent and randomization

Disqualifiers

None

Trial design

Design model

Parallel

Treatments tested in this trial

  • High Driving Pressure Mechanical Ventilation

    Other intervention

    A participant who is already invasively mechanically ventilated will be placed on "Pressure Control Ventilation" mode on an Evita V500 (Manufacturer: Dräger, Lübeck, Germany) ventilator if they are not already. The driving pressure will be set to 25 cmH2O (rate of pressure delivery). The Children's Hospital of Philadelphia (CHOP) PICU's standard of care regarding sedation, fluid management, ventilator weaning, and extubation readiness for invasively mechanically ventilated children will be adhered to for the duration of the study. An Enlight 2100 Electrical Impedance Tomography (EIT) Device (Manufacturer: Timpel) strap will be placed across the participant's chest up to four times throughout the study for a few hours to image the aeration in the lungs.

  • Low Driving Pressure Mechanical Ventilation

    Other intervention

    A participant who is already invasively mechanically ventilated will be placed on "Pressure Control Ventilation" mode on an Evita V500 (Manufacturer: Lübeck, Germany) ventilator if they are not already. The driving pressure will be set to 15 cmH2O (rate of pressure delivery). CHOP PICU's standard of care regarding sedation, fluid management, ventilator weaning, and extubation readiness for invasively mechanically ventilated children will be adhered to for the duration of the study. An Enlight 2100 (EIT) Device (Manufacturer: Timpel) strap will be placed across the participant's chest up to four times throughout the study for a few hours to image the aeration in the lungs.

Treatment groups

160 Participants
are divided into 2 treatment groups
Group A: High Driving Pressure Mechanical VentilationActive comparator 1 intervention
Group B: Low Driving Pressure Mechanical VentilationActive comparator 1 intervention

Trial outcomes

Primary outcomes

1

Sustained Resolution of Hypoxemia

The primary outcome of PARMA is time (in hours) per participant to sustained resolution of hypoxemia, defined as being alive with PaO2/FIO2 (measurement of the amount of oxygen dissolved in the blood plasma/concentration of inhaled oxygen) \> 300 (or SpO2/FIO2 (measurement of the percentage of hemoglobin in your blood that is carrying oxygen/concentration of inhaled oxygen) \> 315) on two consecutive measurements 4 hours apart. This outcome is censored at 28 days (672 hours).

Time frame
Up to 672 hours

Secondary outcomes

1

Imaging (Electrical Impedance Tomography (EIT)): Lung recruitment

EIT (Electronic Impedance Tomography) is an FDA-approved non-radiating method of imaging lung aeration. EIT bands are placed on the subject and EIT imaging will be performed at three time points to assess the assigned study arm. The percentage of patients with recruited lung at the immediate post-randomization EIT, relative to pre-randomization EIT measurement will be determined.

Time frame
Once from time of enrollment to randomization, once within 8 hours post-randomization and once within 24-72 hours after randomization.
2

Imaging (Electrical Impedance Tomography (EIT)): Overdistension

EIT (Electronic Impedance Tomography) is an FDA-approved non-radiating method of imaging lung aeration. EIT bands are placed on the subject and EIT imaging will be performed at three time points to assess the assigned study arm. The percentage of patients with overdistended lung at the immediate post-randomization EIT, relative to pre-randomization EIT measurement will be determined.

Time frame
Once from time of enrollment to randomization, once within 8 hours post-randomization and once within 24-72 hours after randomization.
3

Imaging (Electrical Impedance Tomography (EIT)): Center of Ventilation

EIT (Electronic Impedance Tomography) is an FDA-approved non-radiating method of imaging lung aeration. EIT bands are placed on the subject and EIT imaging will be performed at three time points to assess the assigned study arm. The average value of center of ventilation for each study arm at the immediate post-randomization EIT will be compared.

Time frame
Once from time of enrollment to randomization, once within 8 hours post-randomization and once within 24-72 hours after randomization.
4

Clinical End Point: all-cause mortality at 90 days

Total number of participants all-cause mortality at 90 days after enrollment or hospital discharge.

Time frame
From enrollment up to hospital discharge, no longer than 90 days.

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Children's Hospital of Philadelphia

Lead sponsor

University of Pennsylvania

Collaborator